|Articles|July 1, 2013

Improve drug properties and production with spray drying

GEA Process Engineering offers a full range of spray drying units and services covering the complete development cycle.

Improve drug properties and production with spray drying

Spray drying is a technique preferred by a growing number of pharmaceutical companies to produce better drugs. This ultra-fast and gentle drying technology offers unique possibilities of producing powders with advanced properties - even under aseptic conditions.

Several companies are already benefitting from the technology as an ‘enabling technology’ — to improve the performance of poorly soluble APIs by producing an amorphous solid dispersion, to obtain controlled release or taste-masking, or to produce advanced powders with specific properties.

GEA Process Engineering - the company behind GEA Niro spray drying technology — is the leading provider of spray drying technology to the pharmaceutical industry, and is one of the few companies that offer a full range of spray drying units and services to companies working with the develop-ment of spray dried pharmaceuticals and pharmaceutical grade products. Our portfolio covers the complete development cycle - from the initial proof of concept tests where only a few milliliters of material are available to full-scale production of clinical trial materials and commercial products under cGMP conditions. For better results on any scale, look to GEA Process Engineering.

Company name:  GEA Process Engineering
Website: www.niro.com
E-mail: gea-niro.pharma@gea.com

Related to this article

Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
AAPS PharmSci 360: CMC Strategies, Part 3
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.